How 2 FDA citations complicate Hengrui, Elevar’s push for liver cancer combo approval

Even though Hengrui Pharma has resolved the manufacturing problems cited in a recent FDA complete response letter, a second citation stands in the way of the company and its partner Elevar Therapeu | Even though Hengrui Pharma has resolved the manufacturing problems cited in a recent FDA complete response letter, a second citation stands in the way of the company and its partner Elevar Therapeutics’ fourth attempt at an approval for their liver cancer combination.